EGFR and adenocarcinoma: Four months prior to the admission, he had been diagnosed with unresectable adenocarcinoma (clinical stage IIIA/T4N1M0; an activating EGFR-mutation [L858R]-positive; proportion of tumor expressing PD-L1, 50–74%) originating from the right lower lobe (Figs. 1, 2, and 3).